Regulation and licensing: the CRISPR conundrum continues

In January 2018, The Wall Street Journal issued a fascinating report into clinical trials in China. Since 2015, the report said, scientists have used the now well-known CRISPR technology on at least 86 cancer patients. China is believed to be the first country in the world to test CRISPR on humans. According to doctors quoted in the article, 15 patients had died during the trials, but those deaths were caused by the diseases they were suffering from.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

AstraZeneca to launch CRISPR-based cancer research centre

11 December 2018 Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

Europe

Broad Institute to appeal CRISPR patent revocation

17 January 2018 The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office to revoke one of its patents covering CRISPR/Cas9 technology.

Europe

Are the Broad Institute’s CRISPR patents too broad?

29 October 2015 Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.

More on this story

Biotechnology

AstraZeneca to launch CRISPR-based cancer research centre

11 December 2018 Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

Europe

Broad Institute to appeal CRISPR patent revocation

17 January 2018 The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office to revoke one of its patents covering CRISPR/Cas9 technology.

Europe

Are the Broad Institute’s CRISPR patents too broad?

More on this story

Biotechnology

AstraZeneca to launch CRISPR-based cancer research centre

11 December 2018 Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.

Europe

Broad Institute to appeal CRISPR patent revocation

17 January 2018 The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office to revoke one of its patents covering CRISPR/Cas9 technology.

Europe

Are the Broad Institute’s CRISPR patents too broad?